Redcare Pharmacy (Shop Apoth) Stock (NL0012044747): Jefferies reiterates Buy after sharp guidance hike

Responsible: ad hoc news Stocks & Analysis Desk. Reviewed prior to publication on June 15, 2026 at 10:03:20 PM ET. Details in the imprint.

Redcare Pharmacy shares surged in German trading on Monday after the online pharmacy sharply raised its guidance for 2026, with the move quickly echoed by Wall Street research as Jefferies reiterated its Buy rating and 83 euro price target on the stock. On Xetra, the shares last traded at about 57.30 euros, up roughly 17.4 percent on the day and at their highest level in around three months, putting the MDAX-listed company among the strongest movers in Frankfurt. The guidance upgrade reflects stronger-than-expected momentum in the second quarter and a more confident outlook for both revenue growth and profitability in the coming years. For U.S. investors following European e-commerce and health care names, the combination of a double-digit price reaction and fresh analyst commentary has pulled Redcare Pharmacy (Shop Apoth) firmly into focus.

Jefferies stands by Buy as Redcare lifts 2026 growth and margin targets

Jefferies confirmed its positive stance on Redcare Pharmacy on June 15, 2026, keeping a Buy rating and an 83 euro price target in place after the company raised its 2026 outlook. According to a summary of the note, the analyst firm responded to Redcare's updated guidance by emphasizing the improved medium-term profile while leaving its existing target unchanged, which still implies substantial upside from current levels even after Monday's rally. With the stock around 56 to 57 euros in late trading, Jefferies' 83 euro target represents a potential upside of roughly 45 to 50 percent based on the latest Tradegate and Xetra indications cited in market reports. That gap highlights that, in the view of this particular analyst, the recent price spike has not yet fully closed the valuation distance to its fundamental scenario, even though the stock has already moved sharply higher since the start of the session.

The Jefferies report came directly in response to Redcare's decision to raise its 2026 guidance following what management described as a strong performance so far in the second quarter. Several German financial media outlets and newswires reported that the company now expects consolidated revenue to rise by about 15 to 17 percent in 2026, compared with a previous forecast of roughly 13 to 15 percent. This acceleration in the top-line target suggests that management sees structurally stronger demand across its core markets, including Germany, and potentially improving customer acquisition or order frequency metrics in its main online pharmacy and OTC operations. For investors who track earnings revisions and guidance changes, such a shift in the official revenue corridor is often viewed as a tangible sign that recent business trends are coming in ahead of internal planning assumptions.

Alongside the higher revenue ambition, Redcare also raised its profitability goals for 2026, another key factor behind the analyst reaction and the sharp share-price move. The company now targets an adjusted EBITDA margin of around 2.5 to 3.0 percent for 2026, according to commentary in German-language reports, compared with a previously lower range that had signaled a more gradual climb in earnings leverage. While those margin levels may still look modest compared with some high-margin digital businesses, they represent a notable increase from earlier expectations in a sector that is often characterized by intense competition, significant logistics costs, and ongoing investments in technology and customer acquisition. Jefferies' decision to maintain its Buy rating in the wake of these changes underscores that the research house sees the updated numbers as supportive of its existing investment case for Redcare rather than a reason to temper expectations.

Market data from Xetra and other venues illustrate how powerful the stock reaction has been in the wake of the guidance news and the analyst reiteration. On Xetra, Redcare shares were recently quoted at about 57.30 euros around 17:37 local time, representing a gain of roughly 17.37 percent versus the prior close and putting the stock at the upper end of its intraday range for the session. Separate tickers cited by financial portals show Tradegate quotes near 56.30 euros late in the day, with the stock still up over 15 percent at around 21:49, indicating that much of the move held into the evening as liquidity shifted to other trading venues. A report from finanzen.net highlighted that the shares reached around 56.70 euros at one point on Monday, an increase of roughly 16.1 percent that marked the highest level since early March and pushed the stock back toward the upper part of its recent trading band. Elevated trading volumes on Xetra, with more than 300,000 shares changing hands and day turnover well above recent averages, suggest that the guidance update drew in both existing holders and new investors reacting to the improved outlook.

German broker commentary and financial press coverage emphasized that the stock's sharp advance came directly after Redcare published its updated outlook early on Monday. According to a dpa-AFX broker report summarized by several outlets, the shares jumped quickly at the open and extended gains as the session progressed, driven by a combination of short covering, momentum buying, and fundamental investors rebalancing their exposure following the guidance revision. One widely cited article noted that Redcare's stock was among the top performers in the MDAX, the mid-cap index of the Frankfurt Stock Exchange, underlining how strongly the market rewarded the guidance change relative to most other German equities on the day. For portfolio managers and retail traders alike, such a pronounced reaction can be a signal that expectations for earnings in 2026 and beyond are being recalibrated upward across the market, not just by a single analyst or institution.

The underlying guidance revision itself is rooted in Redcare's operational performance in the first half of the year and especially in the current second quarter, according to an EQS news release and related coverage. The company indicated that growth is running ahead of plan in both its core German operations and its broader European footprint, which includes multiple markets where it offers prescription drugs, over-the-counter products, and related health items through online channels. In particular, Redcare expects stronger revenue from its German business with prescription medicines, where reports cite a new 2026 revenue corridor in the range of roughly 680 to 720 million euros, reflecting higher anticipated demand and efficiency gains in fulfilling orders. At the group level, the 15 to 17 percent revenue growth target for 2026 implies that management believes it can sustain double-digit expansion even as the business grows in absolute size and the regulatory and competitive environment evolves.

From a profitability perspective, the revised adjusted EBITDA margin guidance of around 2.5 to 3.0 percent in 2026 indicates that Redcare aims to balance continued growth investments with greater cost discipline and operational leverage. Media coverage of the guidance update noted that management expects margins to improve as order volumes rise, logistics and fulfillment networks operate at higher utilization, and marketing expenses normalize relative to revenue. For some investors, the new margin range may still appear conservative given the scale potential of an online-only model, while others may view it as a prudent step toward sustainable profitability in a market where regulatory frameworks and reimbursement schemes can change. In the Jefferies note, the analyst's decision to keep the 83 euro target untouched suggests that the new margin outlook is broadly aligned with their prior assumptions, and that the main impact of the update is to reinforce confidence in management's ability to deliver on the existing trajectory rather than to trigger a wholesale revision of the valuation case.

Analyst reports and newswire summaries also pointed out that Redcare remains a relatively prominent name within the European online pharmacy space, which itself is still in a phase of structural transition. The company, formerly known as Shop Apotheke, competes with traditional brick-and-mortar pharmacies as well as other digital players, and its strategy is centered on winning market share in prescription and non-prescription medicines by offering a broad assortment, competitive pricing, and digital convenience. Guidance increases such as Monday's move are often interpreted as a sign that the shift toward online ordering is gaining traction in key continental European markets, although the pace of adoption can vary by country due to differences in regulation, insurance systems, and consumer behavior. Within this framework, Jefferies' ongoing Buy rating highlights that at least one major research house views Redcare as well positioned to benefit from these structural shifts, subject to execution and competitive dynamics.

For U.S. retail investors, Redcare Pharmacy is primarily accessible via European trading venues rather than major U.S. exchanges, so it does not feature among Nasdaq or NYSE listings and is not a constituent of benchmarks such as the S&P 500 or Dow Jones Industrial Average. The stock trades under the ticker RDC in Germany and is part of the MDAX index of mid-cap German equities, with the primary listing on Xetra and quotes available in euros. As a Dutch company with headquarters in Sevenum in the Netherlands, Redcare's reporting is governed by European regulatory standards, and its investor relations materials, including presentations and reports, are available through its corporate website and dedicated investor relations portal. While the absence of a U.S. listing may limit direct inclusion in some U.S.-focused portfolios, the name can still be relevant for investors who seek exposure to European e-commerce, digital health, or online pharmacy themes and who have access to international trading via their brokerage platforms.

Overall, Monday's combination of a sizable guidance increase, a double-digit intraday share-price move, and a reaffirmed Buy rating with a substantial implied upside from Jefferies ensures that Redcare Pharmacy (Shop Apoth) will remain on many watchlists in the near term. The updated revenue and margin targets for 2026 provide a clearer picture of how management currently sees the balance between growth and profitability in its core markets, and they form a new reference point for future quarterly updates and analyst revisions. For investors watching the stock, the key variables to monitor going forward will include the pace of revenue expansion in Germany and other European markets, the trajectory of adjusted EBITDA margins relative to the new 2.5 to 3.0 percent range, and any further changes in analyst sentiment as additional data points become available.

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.